Cancer – AAML1531: Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Condition or Therapy:
Acute Myeloid Leukemia (AML), Down syndrome
Cancer and Blood Disorders
Study Number: AAML1531
What is the goal of this study?
This study assesses response-based chemotherapy in treating newly diagnosed acute myeloid leukemia in patients with Down syndrome.
Who can join the study?
This study may be a good fit for children and young adults who:
- are between 21 days and 3 years old,
- have Down syndrome, and
- have previously untreated de novo AML.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.